The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).
 
Yulia Volchek
No Relationships to Disclose
 
Eran Zimran
No Relationships to Disclose
 
Ilya Kirgner
No Relationships to Disclose
 
Lina Yin
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Rushdia Yusuf
No Relationships to Disclose
 
Burak Gumuscu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
David M. Ross
Honoraria - Novartis
Consulting or Advisory Role - Avance CRO (Inst); Keros Therapeutics (Inst); Menarini (Inst); Novartis (Inst); Takeda (Inst)
Research Funding - GlaxoSmithKline (Inst); Incyte (Inst); Keros Therapeutics (Inst); MorphoSys (Inst); MSD (Inst); Novartis (Inst); Protagonist Therapeutics (Inst); Sumitomo Pharma Oncology (Inst)